AEON Biopharma, Inc.
News
(2)April 2026
AEON Biopharma, Inc. — 8-K Filing
# 🧾 What This Document Is This is a press release filed with the SEC as an exhibit to a Form 8-K. Its purpose is to officially inform investors that AEON Biopharma has received a second notice from the NYSE American exchange about falling short of its financial listing standards. It clarifies that
March 2026
AEON Biopharma, Inc. — 8-K Filing
# 🧾 What This Document Is This is an **8-K filing**, which is like a major news bulletin a public company must send to the SEC. It announces important events. This specific filing contains a press release with two main stories: **AEON Biopharma's 2025 financial results** and **significant progress
Peers in Biotechnology
Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.